10/9/2012 7:59:30 AM
Eli Lilly and Co. is betting on a "broad" range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, says Enrique Conterno, president of Lilly Diabetes. Indianapolis-based Lilly is working on two experimental long-acting insulins, including a version of Sanofi's top-selling Lantus, and therapies in all the main new classes of diabetes drugs, such as a GLP-1 agonist and a SGLT2 inhibitor. "No one that I am aware about has this kind of pipeline," Conterno said in an interview in Berlin, where he was attending the European Association for the Study of Diabetes conference. "Some companies are much more focused on one or two classes, some are more focused on one product. This will provide us a competitive advantage. We like where we stand."
comments powered by